Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders (QoQ) (2014 - 2026)
Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders (QoQ) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Collegium Pharmaceutical | 897.05 Mn | 747.74 Mn | 110.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -203.83% |
| Mar 31, 2026 | -14.54% |
| Dec 31, 2025 | -46.16% |
| Sep 30, 2025 | 162.93% |
| Jun 30, 2025 | 395.78% |
| Mar 31, 2025 | -80.72% |
| Dec 31, 2024 | 34.29% |
| Sep 30, 2024 | -52.39% |
| Jun 30, 2024 | -29.25% |
| Mar 31, 2024 | -13.23% |
| Dec 31, 2023 | 54.79% |
| Sep 30, 2023 | 58.64% |
| Jun 30, 2023 | 174.64% |
| Mar 31, 2023 | -142.06% |
| Dec 31, 2022 | -1,675.27% |
| Sep 30, 2022 | 108.80% |
| Jun 30, 2022 | 60.28% |
| Mar 31, 2022 | 47.79% |
| Dec 31, 2021 | -411.14% |
| Sep 30, 2021 | -89.13% |